Mediclinic Middle East Report issue

Academic/Hospital Phase 2 Phase 3

Organization Overview

First Clinical Trial
2019
NCT03879174
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Hospital Director- Mediclinic City Hospital | Mediclinic Middle East

Active Ingredients

Drugs in Phase 3 Trials (1)

frondanol (1 trial)

Drugs in Phase 2 Trials (2)

pembrolizumab (keytruda) (1 trial)

tamoxifen (nolvadex) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Breast Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 2
  • # of Trial APIs: 3